Asset Details
Do you wish to reserve the book?
Cancer metabolomic markers in urine: evidence, techniques and recommendations
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cancer metabolomic markers in urine: evidence, techniques and recommendations
Do you wish to request the book?
Cancer metabolomic markers in urine: evidence, techniques and recommendations
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cancer metabolomic markers in urine: evidence, techniques and recommendations
2019
Overview
Urinary tests have been used as noninvasive, cost-effective tools for screening, diagnosis and monitoring of diseases since ancient times. As we progress through the 21st century, modern analytical platforms have enabled effective measurement of metabolites, with promising results for both a deeper understanding of cancer pathophysiology and, ultimately, clinical translation. The first study to measure metabolomic urinary cancer biomarkers using NMR and mass spectrometry (MS) was published in 2006 and, since then, these techniques have been used to detect cancers of the urological system (kidney, prostate and bladder) and nonurological tumours including those of the breast, ovary, lung, liver, gastrointestinal tract, pancreas, bone and blood. This growing field warrants an assessment of the current status of research developments and recommendations to help systematize future research.Urinalysis has long been used as a tool for managing diseases, but 21st century techniques have enabled measurement of metabolomic urinary cancer biomarkers using NMR and mass spectrometry. In this Review, the authors discuss the current status of research developments and offer recommendations to help systematize future research in the field.
Publisher
Nature Publishing Group
Subject
